Ask VialBase
Raid · FDA

Amino Asylum FDA Raid — First Physical Enforcement Action Against Peptide Vendor — VialBase News

Last updated · June 15, 2025

Amino Asylum FDA Raid — First Physical Enforcement Against a Peptide Vendor

Summary

In June 2025, the FDA conducted a physical raid on Amino Asylum’s warehouse in Memphis, Tennessee — the first known raid on a major peptide vendor. The site went dark overnight with no warning to customers. Payment processing was cut, and thousands of pending orders were frozen. This marked a significant escalation from the warning-letter approach the FDA had used previously.

Background

Amino Asylum was one of the largest players in the research chemical community, offering a wide catalog including:

What triggered the raid:

  1. Ignored warning letters: The FDA had sent multiple warning letters prior to the raid, all of which Amino Asylum ignored
  2. Marketing for human consumption: Despite “research use only” labels, marketing materials and website copy implied human use
  3. Selling prescription-only substances: Some products fell under prescription-only classifications
  4. Scale of operations: Amino Asylum was operating at a scale that drew federal attention

How it happened:

  • FDA agents arrived at the Memphis warehouse unannounced
  • The website went offline overnight — no customer notification, no wind-down period
  • Payment processing was immediately terminated
  • Thousands of pending orders were frozen mid-fulfillment

Impact

  • Industry shock: This was the first time the FDA physically raided a research peptide vendor rather than just sending letters
  • End of “research use only” defense: The raid demonstrated that the disclaimer no longer provided meaningful legal protection
  • Customer disruption: Thousands of customers lost access to pending orders with no recourse
  • Vendor exodus: Multiple smaller vendors went dark or relocated offshore in the weeks following the raid
  • Precedent for future actions: Established that physical enforcement was now on the table for peptide vendors
  • Connected to broader crackdown: The raid occurred in the same enforcement wave as the GLP-1 warning letters and DOJ criminal prosecutions

What This Means for Researchers

  • Physical raids are now part of the FDA’s enforcement toolkit for the peptide space
  • Vendors who ignore warning letters face escalation to physical enforcement
  • Customers of grey-market vendors carry real risk: orders can be frozen, personal information may be seized
  • The “research use only” label is not a legal shield — the FDA looks at actual marketing intent and customer base
  • Domestic vendors are more vulnerable than offshore ones, but the FDA is expanding international cooperation

Sources